Ashwagandha (Withania somnifera) in insulin resistance and metabolic syndrome: A literature review on mechanisms

Articles in Press

Document Type : Review Article

Authors

1 Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

3 Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

10.22038/ijbms.2025.86747.18741

Abstract

Metabolic syndrome is characterized by obesity, insulin resistance, dyslipidemia, and hypertension. Withania somnifera, commonly known as ashwagandha or Indian winter cherry, belongs to the Solanaceae family. W. somnifera, particularly its powdered root, is a fundamental component of traditional Indian medicine. W. somnifera (Ashwagandha) exhibits pharmacological activities, including immunomodulatory, anti-stress, and neuroprotective effects in animal models. Also, preclinical and clinical studies demonstrate its anti-inflammatory and antiviral properties. In rodent studies, ashwagandha regulates apoptosis and modulates reactive oxygen species (ROS) levels as well as mitochondrial activity. Additionally, it improves endothelial function in rats, dogs, and human brain endothelial cells. Research conducted in both living organisms and controlled laboratory conditions has demonstrated that W. somnifera alleviates the symptoms of metabolic syndrome. It positively affects diabetes by inhibiting dipeptidyl peptidase-4 (DPP-4), α-glucosidase, and α-amylase, while simultaneously increasing pancreatic insulin secretion and improving insulin sensitivity in organs. It has a vasodilatory and diuretic effect. Ashwagandha reduces the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. It modulates the gene expression of peroxisome proliferator-activated receptor (PPAR)-γ. It regulates the gene expression of sterol regulatory element-binding protein (SREBP)-1c and CYP7A1. It increases the secretion of bile acids that eliminate excess cholesterol. It reduces oxidative stress and inflammation while protecting the body from the harmful effects of elevated cholesterol. This study aims to compile a variety of research findings on the effectiveness of ashwagandha in managing metabolic syndrome.

Keywords

Main Subjects

References

1. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. Am J Med 2006; 119:812-819.
2. Kim TN, Kim JM, Won JC, Park MS, Lee SK, Yoon SH, et al. A decision tree-based approach for identifying urban-rural differences in metabolic syndrome risk factors in the adult korean population. J Endocrinol Invest 2012; 35:847-852.
3. Mohamed SM, Shalaby MA, El-Shiekh RA, El-Banna HA, Emam SR, Bakr AF. Metabolic syndrome: Risk factors, diagnosis, pathogenesis, and management with natural approaches. FoodChem Adv 2023; 3:100335.
4. Islam MS, Wei P, Suzauddula M, Nime I, Feroz F, Acharjee M, et al. The interplay of factors in metabolic syndrome: understanding its roots and complexity. Mol Med 2024;30:279-299.
5. Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: From obesity to metabolic syndrome and diabetes. Diabetology & Metabolic Syndrome 2020; 12:60-79.
6. Egan BM. Insulin resistance and the sympathetic nervous system. Current hypertension Reports 2003; 5:247-254.
7. Talha J, Priyanka M, Akanksha A. Hypertension and herbal plants. Int Res J Pharm 2011;2:26-30.
8. Radosavljevic T, Brankovic M, Samardzic J, Djuretić J, Vukicevic D, Vucevic D, Jakovljevic V. Altered mitochondrial function in MASLD: key features and promising therapeutic approaches. Antioxidants 2024; 13:906-923.
9. Maiorana A, Tagliaferri F, Dionisi-Vici C. Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders. Front Endocrinol (Lausanne) 2023; 14:1145111.
10. Wong SK. Repurposing new use for old drug chloroquine against metabolic syndrome: A review on animal and human evidence. Int J Med Sci 2021; 18:2673-2688.
11. Rameshrad M, Razavi BM, Lalau JD, De Broe ME, Hosseinzadeh H. An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning. Iran J Basic Med Sci 2020; 23:556-568.
12. Rameshrad M, Razavi BM, Ferns GAA, Hosseinzadeh H. Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: A comprehensive review on drug repositioning. Daru 2019; 27:341-360.
13. Mansouri M, Imenshahidi M, Rameshrad M, Hosseinzadeh H. Effects of Tinospora cordifolia (giloy) on metabolic syndrome components: A mechanistic review. Naunyn Schmiedebergs Arch Pharmacol 2025;398:4979-5009.
14. Ghasemzadeh Rahbardar M, Fazeli Kakhki H, Hosseinzadeh H. Ziziphus jujuba (Jujube) in metabolic syndrome: from traditional medicine to scientific validation. Curr Nutr Rep 2024; 13:845-866.
15. Samei M, Dowlatkhahi N, Boozari M, Hosseinzadeh H. Can daily consumption of enriched fatty acids diet be effective in improving metabolic syndrome? an attractive paradox for walnut kernel. Food Sci Nutr 2024; 12:2311-2333.
16. Scandar S, Zadra C, Marcotullio MC. Coriander (Coriandrum sativum) polyphenols and their nutraceutical value against obesity and metabolic syndrome. Molecules 2023; 28:4187-4198.
17. Ebrahimian Z, Razavi BM, Mousavi Shaegh SA, Hosseinzadeh H. Effects of Portulaca oleracea L. (purslane) on the metabolic syndrome: A review. Iran J Basic Med Sci 2022; 25:1275-1285.
18. Salaramoli S, Mehri S, Yarmohammadi F, Hashemy SI, Hosseinzadeh H. The effects of ginger and its constituents in the prevention of metabolic syndrome: A review. Iran J Basic Med Sci 2022; 25:664-674.
19. Aminifard T, Razavi BM, Hosseinzadeh H. The effects of ginseng on the metabolic syndrome: An updated review. Food Sci Nutr 2021; 9:5293-5311.
20. Yarmohammadi F, Ghasemzadeh Rahbardar M, Hosseinzadeh H. Effect of eggplant (Solanum melongena) on the metabolic syndrome: A review. Iran J Basic Med Sci 2021; 24:420-427.
21. Mahdian D, Abbaszadeh-Goudarzi K, Raoofi A, Dadashizadeh G, Abroudi M, Zarepour E, Hosseinzadeh H. Effect of Boswellia species on the metabolic syndrome: A review. Iran J Basic Med Sci 2020; 23:1374-1381.
22. Esmaeilzadeh D, Razavi BM, Hosseinzadeh H. Effect of Abelmoschus esculentus (okra) on metabolic syndrome: A review. Phytother Res 2020; 34:2192-2202.
23. Eisvand F, Razavi BM, Hosseinzadeh H. The effects of Ginkgo biloba on metabolic syndrome: A review. Phytother Res 2020; 34:1798-1811.
24. Dehghani S, Mehri S, Hosseinzadeh H. The effects of Crataegus pinnatifida (Chinese hawthorn) on metabolic syndrome: A review. Iran J Basic Med Sci 2019; 22:460-468.
25. Shakib Z, Shahraki N, Razavi BM, Hosseinzadeh H. Aloe vera as an herbal medicine in the treatment of metabolic syndrome: A review. Phytother Res 2019; 33:2649-2660.
26. Tajmohammadi A, Razavi BM, Hosseinzadeh H. Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: A review. Phytother Res 2018; 32:1933-1949.
27. Sanati S, Razavi BM, Hosseinzadeh H. A review of the effects of Capsicum annuum L. and its constituent, capsaicin, in metabolic syndrome. Iran J Basic Med Sci 2018; 21:439-448.
28. Tabeshpour J, Razavi BM, Hosseinzadeh H. Effects of Avocado (Persea americana) on metabolic syndrome: A comprehensive systematic review. Phytother Res 2017; 31:819-837.
29. Tousian Shandiz H, Razavi BM, Hosseinzadeh H. Review of Garcinia mangostana and its xanthones in metabolic syndrome and related complications. Phytother Res 2017; 31:1173-1182.
30. Tabeshpour J, Imenshahidi M, Hosseinzadeh H. A review of the effects of Berberis vulgaris and its major component, berberine, in metabolic syndrome. Iran J Basic Med Sci 2017; 20:557-568.
31. Hassani FV, Shirani K, Hosseinzadeh H. Rosemary (Rosmarinus officinalis) as a potential therapeutic plant in metabolic syndrome: A review. Naunyn Schmiedebergs Arch Pharmacol 2016; 389:931-949.
32. Akaberi M, Hosseinzadeh H. Grapes (Vitis vinifera) as a potential candidate for the therapy of the metabolic syndrome. Phytother Res 2016; 30:540-556.
33. Hosseini A, Hosseinzadeh H. A review on the effects of Allium sativum (Garlic) in metabolic syndrome. J Endocrinol Invest 2015; 38:1147-1157.
34. Razavi BM, Hosseinzadeh H. A review of the effects of Nigella sativa L. and its constituent, thymoquinone, in metabolic syndrome. J Endocrinol Invest 2014; 37:1031-1040.
35. Ahmad M, Dar NJ. 8 - Withania somnifera: Ethnobotany, pharmacology, and therapeutic functions. In: Bagchi D, editor. Sustained Energy for Enhanced Human Functions and Activity: Academic Press; 2017. p. 137-154.
36. Macharia JM, Káposztás Z, Bence RL. Medicinal characteristics of Withania somnifera L. In colorectal cancer management. Pharmaceuticals (Basel) 2023; 16:915.
37. Gaurav H, Yadav D, Maurya A, Yadav H, Yadav R, Shukla AC, et al. Biodiversity, biochemical profiling, and pharmaco-commercial applications of Withania somnifera: A review. Molecules 2023; 28:1208-1234.
38. Mandlik DS, Namdeo AG. Pharmacological evaluation of ashwagandha highlighting its healthcare claims, safety, and toxicity aspects. J Diet Suppl 2021; 18:183-226.
39. Tiwari R, Chakraborty S, Saminathan M, Dhama K, Singh SV. Ashwagandha (Withania somnifera): Role in safeguarding health, immunomodulatory effects, combating infections and therapeutic applications: A review. J Biol Sci 2014; 14:77-94.
40. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): A review. Altern Med Rev 2000; 5:334-346.
41. Paul S, Chakraborty S, Anand U, Dey S, Nandy S, Ghorai M, et al. Withania somnifera (L.) Dunal (Ashwagandha): A comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological aspects. Biomed Pharmacother 2021; 143: 112175.
42. Langade D, Kanchi S, Salve J, Debnath K, Ambegaokar D. Efficacy and safety of Ashwagandha (Withania somnifera) root extract in insomnia and anxiety: A double-blind, randomized, placebo-controlled study. Cureus 2019; 11:e5797.
43. Połumackanycz M, Forencewicz A, Wesołowski M, Viapiana AA. The plant with proven health-promoting properties. Farm Pol 2020; 76:442-447.
44. Mirjalili MH, Moyano E, Bonfill M, Cusido RM, Palazón J. Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules 2009; 14:2373-2393.
45. Bhattacharya SK, Goel RK, Kaur R, Ghosal S. Anti‐stress activity of sitoindosides VII and VIII, new acylsterylglucosides from Withania somnifera. Phytother Rese 1987; 1:32-37.
46. Ghosal S, Lal J, Srivastava R, Bhattacharya SK, Upadhyay SN, Jaiswal AK, Chattopadhyay U. Immunomodulatory and CNS effects of sitoindosides IX and X, two new glycowithanolides from Withania somnifera. Phytotherapy Research 1989; 3:201-206.
47. Mikulska P, Malinowska M, Ignacyk M, Szustowski P, Nowak J, Pesta K, et al. Ashwagandha (Withania somnifera)-current research on the health-promoting activities: A narrative review. Pharmaceutics 2023; 15:1057-1090.
48. Bhattacharya A, Ramanathan M, Ghosal S, Bhattacharya SK. Effect of Withania somnifera glycowithanolides on iron-induced hepatotoxicity in rats. Phytother Res 2000; 14:568-570.
49. Kuboyama T, Tohda C, Komatsu K. Neuritic regeneration and synaptic reconstruction induced by withanolide A. Br J Pharmacol 2005; 144:961-971.
50. Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S. Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: an experimental study. Phytomedicine 2000; 7:463-469.
51. Ahmad M, Saleem S, Ahmad AS, Ansari MA, Yousuf S, Hoda MN, Islam F. Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced parkinsonism in rats. Hum Exp Toxicol 2005; 24:137-147.
52. Speers AB, Cabey KA, Soumyanath A, Wright KM. Effects of Withania somnifera (Ashwagandha) on stress and the stress- related neuropsychiatric disorders anxiety, depression, and insomnia. Curr Neuropharmacol 2021; 19:1468-1495.
53. Xia Y, Yan M, Wang P, Hamada K, Yan N, Hao H, et al. Withaferin A in the treatment of liver diseases: progress and pharmacokinetic insights. Drug Metab Dispos 2022; 50:685-693.
54. Saggam A, Limgaokar K, Borse S, Chavan-Gautam P, Dixit S, Tillu G, Patwardhan B. Withania somnifera (L.) Dunal: opportunity for clinical repurposing in covid-19 management. Front Pharmacol 2021; 12:623795.
55. Ko JS, Chang BY, Choi YJ, Choi JS, Kwon HY, Lee JY, et al. Ashwagandha ethanol extract attenuates sarcopenia-related muscle atrophy in aged mice. Nutrients 2024; 16:157-174.
56. Wankhede S, Langade D, Joshi K, Sinha SR, Bhattacharyya S. Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial. J Int Soc Sports Nutr 2015; 12:43-53.
57. Bonilla DA, Moreno Y, Gho C, Petro JL, Odriozola-Martínez A, Kreider RB. Effects of Ashwagandha (Withania somnifera) on physical performance: Systematic review and bayesian meta-analysis. J Funct Morphol Kinesiol 2021; 6:20-50.
58. Prabu PC, Panchapakesan S, Raj CD. Acute and sub-acute oral toxicity assessment of the hydroalcoholic extract of Withania somnifera roots in Wistar rats. Phytother Res 2013; 27:1169-1178.
59. Prabu PC, Panchapakesan S. Prenatal developmental toxicity evaluation of Withania somnifera root extract in Wistar rats. Drug Chem Toxicol 2015; 38:50-56.
60. Kalaivani P, Siva R, Gayathri V, Langade D. Mutagenicity and safety evaluation of Ashwagandha (Withania somnifera) root aqueous extract in different models. Toxicol Rep 2024; 12:41-47.
61. Cheah KL, Norhayati MN, Husniati Yaacob L, Abdul Rahman R. Effect of Ashwagandha (Withania somnifera) extract on sleep: a systematic review and meta-analysis. PLoS One 2021; 16:e0257843.
62. Choudhary D, Bhattacharyya S, Bose S. Efficacy and safety of Ashwagandha (Withania somnifera L.) Dunal) root extract in improving memory and cognitive functions. J Diet Suppl 2017; 14:599-612.
63. Quinones D, Barrow M, Seidler K. Investigating the impact of Ashwagandha and meditation on stress induced obesogenic eating behaviours. J Am Nutr Assoc 2025; 44:68-88.
64. Allah R, Zunaira R, Nehal U, Hina R, Aneela F, Zahoor A, et al. The role of Ashwagandha in metabolic syndrome: A review of traditional knowledge and recent research findings.  Biol Regul Homeost Agents 2023; 37:5091-5103.
65. Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep 2018; 20:12-19.
66. Oyewusi HA, Wu YS, Safi SZ, Wahab RA, Hatta MHM, Batumalaie K. Molecular dynamics simulations reveal the inhibitory mechanism of Withanolide A against α-glucosidase and α-amylase. J Biomol Struct Dyn 2023; 41:6203-6218.
67. Kempegowda PK, Zameer F, Murari SK. Delineating antidiabetic proficiency of catechin from Withania somnifera and its inhibitory action on dipeptidyl peptidase-4 (Dpp-4). Biomed Res (India) 2018; 29:3192-3200.
68. Gorelick J, Rosenberg R, Smotrich A, Hanuš L, Bernstein N. Hypoglycemic activity of withanolides and elicitated Withania somnifera. Phytochemistry 2015; 116:283-289.
69. Borchi E, Bargelli V, Guidotti V, Berti A, Stefani M, Nediani C, Rigacci S. Mild exposure of RIN-5F β-cells to human islet amyloid polypeptide aggregates upregulates antioxidant enzymes via NADPH oxidase-RAGE: An hormetic stimulus. Redox Biology 2014; 2:114-122.
70. Sorelle JA, Itoh T, Peng H, Kanak MA, Sugimoto K, Matsumoto S, et al. Withaferin A inhibits pro-inflammatory cytokine-induced damage to islets in culture and following transplantation. Diabetologia 2013; 56:814-824.
71. Babu PV, Gokulakrishnan A, Dhandayuthabani R, Ameethkhan D, Kumar CV, Ahamed MI. Protective effect of Withania somnifera (Solanaceae) on collagen glycation and cross-linking. Comp Biochem Physiol B Biochem Mol Biol 2007; 147:308-313.
72. Balkrishna A, Kumari P, Singh P, Pathak N, Verma S, Dev R, Varshney A. Withanolides-enriched leaf extract of Withania somnifera exert anti-obesity effects by inducing brown adipocyte-like phenotype via tuning MAP-kinase signaling axis. Int J Biol Macromol 2024; 282:136883.
73. Etesami B, Ghaseminezhad S, Nowrouzi A, Rashidipour M, Yazdanparast R. Investigation of 3T3-L1 cell differentiation to adipocyte, affected by aqueous seed extract of Phoenix Dactylifera L. Rep Biochem Mol Biol 2020; 9:14-25.
74. Malaikozhundan B, Vinodhini J, Kalanjiam MAR, Vinotha V, Palanisamy S, Vijayakumar S, et al. High synergistic antibacterial, antibiofilm, antidiabetic and antimetabolic activity of Withania somnifera leaf extract-assisted zinc oxide nanoparticle. Bioprocess Biosyst Eng 2020; 43:1533-1547.
75. Parihar P, Shetty R, Ghafourifar P, Parihar MS. Increase in oxidative stress and mitochondrial impairment in hypothalamus of streptozotocin treated diabetic rat: Antioxidative effect of Withania somnifera. Cell Mol Biol 2016; 62:73-83.
76. Udayakumar R, Kasthurirengan S, Vasudevan A, Mariashibu TS, Rayan JJS, Choi CW, et al. Antioxidant effect of dietary supplement Withania somnifera L. reduce blood glucose levels in alloxan-induced diabetic rats. Plant Foods Hum Nutr 2010; 65:91-98.
77. Kanitkar M, Bhonde R. Existence of islet regenerating factors within the pancreas. Rev Diabet Stud 2004; 1:185-192.
78. Tang LQ, Wei W, Chen LM, Liu S. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J Ethnopharmacol 2006; 108:109-115.
79. Jain S, Pandhi P, Singh A, Malhotra S. Efficacy of standardised herbal extracts in type 1 diabetes-an experimental study. Afr J Tradit Complement Altern Med 2006; 3:23-33.
80. Tiwari DD, Thorat VM, Pakale PV, Patil SJ. Study of antidiabetic properties of Berberis asiatica and Withania somnifera in streptozotocin-nicotinamide-induced type II diabetes mellitus in Wistar rats. Cureus 2024; 16:e64379.
81. Kiasalari Z, Khalili M, Aghaei M. Effect of Withania somnifera on levels of sex hormones in the diabetic male rats. Iran J Reprod Med 2009; 7:163-168.
82. Kyathanahalli CN, Manjunath MJ, Muralidhara. Oral supplementation of standardized extract of Withania somnifera protects against diabetes-induced testicular oxidative impairments in prepubertal rats. Protoplasma 2014; 251:1021-1029.
83. De Young L, Yu D, Bateman RM, Brock GB. Oxidative stress and antioxidant therapy: their impact in diabetes-associated erectile dysfunction. J Androl 2004; 25:830-836.
84. Shrilatha B. Occurrence of oxidative impairments, response of antioxidant defences and associated biochemical perturbations in male reproductive milieu in the streptozotocin-diabetic rat. Int J Androl 2007; 30:508-518.
85. Chandrashekar KN, Muralidhara. Evidence of oxidative stress and mitochondrial dysfunctions in the testis of prepubertal diabetic rats. Int J Impot Res 2009; 21:198-206.
86. Hashem HA, Nabil ZI, Gad El-Hak HN. Ameliorative effect of Ashwagandha (Withania somnifera) root extract on brain oxidative stress and depression of diabetic rats. J Adv Vet Res 2023; 13:508-514.
87. Wink DA, Hines HB, Cheng RY, Switzer CH, Flores-Santana W, Vitek MP, et al. Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol 2011; 89:873-891.
88. Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004; 25:612-628.
89. Anwer T, Sharma M, Pillai KK, Iqbal M. Effect of Withania somnifera on insulin sensitivity in non-insulin-dependent diabetes mellitus rats. Basic Clin Pharmacol Toxicol 2008; 102:498-503.
90. Udayakumar R, Kasthurirengan S, Mariashibu TS, Rajesh M, Anbazhagan VR, Kim SC, et al. Hypoglycaemic and hypolipidaemic effects of Withania somnifera root and leaf extracts on alloxan-induced diabetic rats. Int J Mol Sci 2009; 10:2367-2382.
91. Jena S, Jena RC, Bhol R, Agarwal K, Sarangi A, Sahu P, Mishra S. A comparative study of the anti-oxidative and antidiabetic potential of in vitro and in vivo root and leaf extracts of Withania somnifera on streptozotocin induced diabetic rats. Int J Pharm Pharm Sci 2016; 8:85-91.
92. K Thakur A, Dey A, S Chatterjee S, Kumar V. Reverse Ayurvedic pharmacology of ashwagandha as an adaptogenic antidiabetic plant: a pilot study. Curr Tradit Med 2015; 1:51-61.
93. Tekula S, Khurana A, Anchi P, Godugu C. Withaferin-A attenuates multiple low doses of streptozotocin (MLD-STZ) induced type 1 diabetes. Biomed Pharmacother 2018; 106:1428-1440.
94. Lee J, Liu J, Feng X, Salazar Hernández MA, Mucka P, Ibi D, et al. Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice. Nature Medicine 2016; 22:1023-1032.
95. Anwer T, Sharma M, Pillai KK, Khan G. Protective effect of Withania somnifera against oxidative stress and pancreatic beta-cell damage in type 2 diabetic rats. Acta Pol Pharm 2012; 69:1095-1101.
96. Ram H, Krishna A. Improvements in insulin resistance and β-cells dysfunction by ddp-4 inhibition potential of Withania somnifera (L.) dunal root extract in type 2 diabetic rat. Biointerface Res Appl Chem 2021; 11:8141-8155.
97. Kumari D, Gautam J, Sharma V, Gupta SK, Sarkar S, Jana P, et al. Effect of herbal extracts and Saroglitazar on high-fat diet-induced obesity, insulin resistance, dyslipidemia, and hepatic lipidome in C57BL/6J mice. Heliyon 2023; 9:e22051.
98. Wang Y, Nakajima T, Gonzalez FJ, Tanaka N. PPARs as metabolic regulators in the liver: Lessons from liver-specific PPAR-null mice. Int J Mol Sci 2020; 21:2061-2075.
99. Lee YK, Park JE, Lee M, Hardwick JP. Hepatic lipid homeostasis by peroxisome proliferator-activated receptor gamma 2. Liver Res 2018; 2:209-215.
100. Holm LJ, Mønsted MØ, Haupt-Jorgensen M, Buschard K. PPARs and the development of type 1 diabetes. PPAR Res 2020;2020:6198628-6198638.
101. Abu Bakar MH, Azmi MN, Shariff KA, Tan JS. Withaferin A protects against high-fat diet-induced obesity via attenuation of oxidative stress, inflammation, and insulin resistance. Appl Biochem Biotechnol 2019; 188:241-259.
102. Mutalik S, Chetana M, Sulochana B, Devi PU, Udupa N. Effect of Dianex, a herbal formulation on experimentally induced diabetes mellitus. Phytother Res 2005; 19:409-415.
103. Andallu B, Radhika B. Hypoglycemic, diuretic and hypocholesterolemic effect of winter cherry (Withania somnifera, Dunal) root. Indian J Exp Biol 2000; 38:607-609.
104. Kifle ZD, Adugna M, Chanie GS, Mohammed A. Prevalence and associated factors of hypertension complications among hypertensive patients at university of gondar comprehensive specialized referral hospital. Clin Epidemiol Glob Health 2022; 13:100951-100956.
105. Ahumada F, Aspee F, Wikman G, Hancke J. Withania somnifera extract - its effect on arterial blood-pressure in anesthetized dogs. Phytother Res 1991; 5:111-114.
106. Kaur G, Singh N, Samuel SS, Bora HK, Sharma S, Pachauri SD, et al. Withania somnifera shows a protective effect in monocrotaline-induced pulmonary hypertension. Pharm Biol 2015; 53:147-157.
107. Dhuley JN. Effect of ashwagandha on lipid peroxidation in stress-induced animals. J Ethnopharmacol 1998; 60:173-178.
108. Pingali U, Pilli R, Fatima N. Effect of Withania somnifera extract on mental stress induced changes in hemodynamic properties and arterial wave reflections in healthy subjects. Curr Top Nutraceutical Res 2013; 11:151-158.
109. Blaton V. How is the metabolic syndrome related to the dyslipidemia? Ejifcc 2007; 18:15-22.
110. Garg R, Aggarwal S, Kumar R, Sharma G. Association of atherosclerosis with dyslipidemia and co-morbid conditions: A descriptive study. J Nat Sci Biol Med 2015; 6:163-168.
111. Haile K, Haile A, Timerga A. Predictors of lipid profile abnormalities among patients with metabolic syndrome in southwest ethiopia: A cross-sectional study. Vasc Health Risk Manag 2021; 17:461-469.
112. Soh S, Ong WY. Effect of Withanolide A on 7-Ketocholesterol induced cytotoxicity in hCMEC/D3 brain endothelial cells. Cells 2022; 11:457-469.
113. Lee SR, Lee BS, Yu JS, Kang H, Yoo MJ, Yi SA, et al. Identification of anti-adipogenic withanolides from the roots of Indian ginseng (Withania somnifera). J Ginseng Res 2022; 46:357-366.
114. Qureshi SR, Sahni YP, Singh SK. Withania somnifera reduces egg yolk total lipids, cholesterol and triglycerides in birds. Res J Pharm Biol Chem Sci 2011; 2:730-739.
115. Pandey S, Sahni AYP. Effect of Withania somnifera on egg cholesterol and production traits in birds. J Vet Pharmacol Tox 2010; 9:64-67.
116. Anwer T, Sharma M, Khan G, Alam MF, Alam N, Ali MS, Alam MS. Preventive role of Withania somnifera on hyperlipidemia and cardiac oxidative stress in streptozotocin induced type 2 diabetic rats. Trop J Pharm Res 2017; 16:119-125.
117. Tiwari DD, Thorat VM, Pakale PV, Patil S, Chavan D. Evaluation of lipid profile modulation by Berberis asiatica, Withania somnifera, and their synergy in type 2 diabetic Wistar rats. Cureus 2024; 16:e67974.
118. Tiwari DD, Thorat VM, Pakale PV, Patil S. Effects of Berberis asiatica, Withania somnifera, and their combination on body weight in streptozotocin-nicotinamide-induced type 2 diabetes in Wistar rats. Cureus 2024; 16:e68295.
119. Visavadiya NP, Narasimhacharya AV. Hypocholesteremic and antioxidant effects of Withania somnifera (Dunal) in hypercholesteremic rats. Phytomedicine 2007; 14:136-142.
120. Laylani L, Saleh AH. Alcoholic extract effect of Withania somnifera roots on cholesterol diet induced hyperlipidemia in male rabbits. Iraqi J Sci 2018; 59:267-270.
121. Lee DH, Park SH, Lee E, Seo HD, Ahn J, Jang YJ, et al. Withaferin A exerts an anti-obesity effect by increasing energy expenditure through thermogenic gene expression in high-fat diet-fed obese mice. Phytomedicine 2021; 82:153457-153464.
122. Ikonen E. Mechanisms for cellular cholesterol transport: Defects and human disease. Physiol Rev 2006; 86:1237-1261.
123. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109:1125-1131.
124. Mary NK, Babu BH, Padikkala J. Antiatherogenic effect of Caps HT2, a herbal Ayurvedic medicine formulation. Phytomedicine 2003; 10:474-482.
125. Devi AJ, Ravindran R, Sankar M, Rajkumar J. Effect of ambrex (a herbal formulation) on oxidative stress in hyperlipidemic rats and differentiation of 3T3-L1 preadipocytes. Pharmacogn Mag 2014; 10:165-171.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 16 September 2025

Files

Share

How to cite

Statistics